Subscribe To
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Cardiff oncology, inc. (crdf) q3 2023 earnings call transcript
Cardiff oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Comp...
November 2, 2023, 9:11 pm
Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – SAN DIE...
November 2, 2023, 11:30 am
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema oncology<...
November 1, 2023, 8:27 pm
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema oncology...
November 1, 2023, 4:27 pm
Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific
– ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action – BRYAN, Texas and ...
November 1, 2023, 12:24 pm
Processa pharmaceuticals announces formation of oncology advisory board with renowned key opinion leaders
Company To Leverage World-Class oncology Advisory Board in the Design of ...
November 1, 2023, 12:15 pm
Sensei biotherapeutics appoints stephanie krebs, ms, mba, as chief business officer
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-...
November 1, 2023, 11:30 am
Celcuity to present at upcoming stifel and jefferies investor conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted ...
November 1, 2023, 11:05 am
Aptevo to present at bio-europe conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing nov...
November 1, 2023, 7:45 am
Celcuity to present at upcoming stifel and jefferies investor conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted t...
November 1, 2023, 7:05 am
Affimed to participate in upcoming investor conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-...
November 1, 2023, 6:30 am
Poolbeg investor meeting will take a deep dive into lead programme
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 ...
November 1, 2023, 3:34 am
Astrazeneca signs drug development deal with biotech cellectis
AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee...
November 1, 2023, 3:17 am
Lirum therapeutics presents positive data on lx-101, a novel clinical-stage targeted therapy, demonstrating potent preclinical activity against pediatric sarcomas
New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focuse...
October 31, 2023, 5:27 pm
Revolution medicines to report financial results for third quarter 2023 after market close on november 6, 2023
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage ...
October 31, 2023, 4:15 pm
Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...
October 31, 2023, 9:15 am
Transcode therapeutics withdraws public offering
BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA ...
October 30, 2023, 8:33 pm
Gilead (gild) gears up to report q3 earnings: what's in store?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when t...
October 30, 2023, 1:32 pm
Kura oncology to participate in three upcoming investor conferences
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura oncology, Inc. (Nasdaq: KURA), a clinical-stage bioph...
October 30, 2023, 7:30 am